Add Resources - Scaling Up & Sustainability

COVID-19 Response in Ethiopia

Ethiopia recorded 372 000 confirmed cases of COVID-19 and around 6800 deaths in the first two years of the pandemic. 

Since March 2022, when the first case was recorded, health facilities diverted all available resources to preventing and treating COVID-19, and this negatively impacted on maternal, newborn, and child health, non-communicable diseases, surgery, and HIV, TB, and malaria. 

Many health facilities closed down completely.

Disruptions in the supply chain system led to a stock-out of essential drugs and a shortage of medical equipment.

The Global Fund supported Ethiopia with US$111.1-million to fight COVID-19, focusing on strengthening the community health system, which is a well-integrated programme in the country. 

Plans are to further assist with surveillance programmes, strengthen laboratory systems, COVID-19 case finding, contact tracing, case management, and home-based isolation and care. 

Further investments also targeted infection prevention and control, risk communication and community engagement, and protecting vulnerable populations.

Add Resources - Scaling Up & Sustainability

COVID-19 Response in Peru

The COVID-19 pandemic had a devastating impact on Peru’s health system and economy.

It is one of the countries with the highest numbers of pandemic-linked excess deaths in the world. 

HIV and TB services were severely disrupted. 

The Global Fund supported Peru with US$14.9-million to fight COVID-19, including support for the procurement of diagnostic tests, personal protective equipment (PPE), and scaling up oxygen support for COVID-19 patients. 

A part of this investment was used to get TB and HIV programmes back on track. This intervention includes the purchase of mobile units (vans) and campaigns to find people with TB, support for patients with multidrug-resistant TB, and the use of a mobile app to help patients with MDR-TB to adhere to their treatment regime. 

Strong community engagement forms an integral part of the programme. This includes community-based disease monitoring and efforts to reduce stigma and discrimination.

Add Resources - Scaling Up & Sustainability

COVID-19 Response in the Philippines

The Philippines has been severely affected by COVID-19, with more than 3 million confirmed cases and around 52 700 deaths by 2022.

Lockdown measures and community quarantines were introduced in March 2022. 

The impact of the pandemic was particularly visible in the TB and HIV programs in the Philippines, with testing numbers dropping across the board. 

In 2021, COVID-19 cases surged again as the Delta variant spread.

The Global Fund supported the Philippines with US$37.7-million to fight COVID-19 in grants for the expansion of testing capacity and support to develop a case management strategy.

Further interventions focused on mitigating the impact of the pandemic on HIV, TB, and malaria programmes.

The Philippines was one of the first countries to develop a strong, comprehensive TB adaptive plan for the impact of COVID-19.

Add Resources - Scaling Up & Sustainability

COVID-19 Response in Thailand

Thailand was the first country outside China to report a COVID-19 case. 

Containment measures, like lockdowns and travel restrictions,  were implemented as early as March 2020. This was initially successful, but devastated the foreign tourism sector, which accounts for around 20% of Thailand’s GDP.

This early success, keeping COVID-19 case numbers low, could not be sustained. 

By the latter part of 2021, the Delta variant became the dominant global strain of SARS-CoV-2, and the health system was overwhelmed by the surge in cases.

The Global Fund assisted Thailand with the procurement of personal protective equipment (PPE) and COVID-19 diagnostic tests. 

A strong focus on local key populations guided the implementation of interventions with the help of broader civil society. 

This inclusive approach allowed for the implementation of tailored measures that were sensitive to the needs of diverse communities.